A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support
about
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.Polymorphisms in the TNFA and IL6 genes represent risk factors for autoimmune thyroid diseaseSingle nucleotide polymorphisms in IL1B and the risk of acute coronary syndrome: a Danish case-cohort study.Colorectal cancer in patients with inflammatory bowel disease: can we predict risk?Genetic variations in multiple myeloma II: association with effect of treatment.Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma.Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.Association of PPP1R13L and CD3EAP polymorphisms with risk and survival of non-small cell lung cancer in Chinese non-smoking females.Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival.Association and interaction of NFKB1 rs28362491 insertion/deletion ATTG polymorphism and PPP1R13L and CD3EAP related to lung cancer risk in a Chinese population.Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib
P2860
Q33649116-A4B81525-A2FA-43DF-B50A-E93382FE7747Q34051020-BE154F2A-C9CE-4B08-ACDA-5FB2D442AF07Q34327966-35329825-D3E8-44A7-9BE3-99015F02DB8BQ36175033-CE938962-511C-431E-AC97-BC7DED8258ECQ37924890-4924A127-E59D-4C8F-9AAD-B40D97B7206CQ39679671-4CEB897D-82EC-43CD-873C-223F44FF8B4EQ42132693-9F816548-25FD-4199-9489-BFBACD4B02B4Q45913850-B6D7685F-D0CE-43F1-AFDB-25C033EDABA7Q47105742-E97DED72-C3DA-445D-8677-BE341803F003Q50588462-53BAC9B6-69FC-459D-9C77-148A2968BB12Q53210875-9E9EC1E8-6F65-40E7-9695-CD0B290478DBQ59245070-D50CFFDC-E246-40C6-A527-C9848D56E377
P2860
A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A polymorphism in NFKB1 is ass ...... eatment with stem cell support
@en
A polymorphism in NFKB1 is ass ...... atment with stem cell support.
@nl
type
label
A polymorphism in NFKB1 is ass ...... eatment with stem cell support
@en
A polymorphism in NFKB1 is ass ...... atment with stem cell support.
@nl
prefLabel
A polymorphism in NFKB1 is ass ...... eatment with stem cell support
@en
A polymorphism in NFKB1 is ass ...... atment with stem cell support.
@nl
P2093
P2860
P1433
P1476
A polymorphism in NFKB1 is ass ...... eatment with stem cell support
@en
P2093
Henrik Gregersen
Niels Abildgaard
Niels F Andersen
Peter Gimsing
Tobias W Klausen
P2860
P304
P356
10.3324/HAEMATOL.2008.004572
P577
2009-09-01T00:00:00Z